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In this study, we identify the bidirectional organic cation transporter 3 (OCT3/Slc22a3) as 
the molecule responsible for histamine uptake by murine basophils. We demonstrate that 
OCT3 participates in the control of basophil functions because exogenous histamine can 
inhibit its own synthesis—and that of interleukin (IL)-4, IL-6, and IL-13—through this 
means of transport. Furthermore, ligands of H
 
3
 
/H
 
4
 
 histamine receptors or OCT3 inhibit 
histamine uptake, and outward transport of newly synthesized histamine. By doing so, they 
increase the histamine content of basophils, which explains why they mimic the effect of 
exogenous histamine. These drugs were no longer effective in histamine-free histidine 
decarboxylase (HDC)-deficient mice, in contrast with histamine itself. Histamine was not 
taken up and lost its inhibitory effect in mice deficient for OCT3, which proved its specific 
involvement. Intracellular histamine levels were increased strongly in IL-3–induced 
 
OCT3
 
 
 
/
 
 
 
 bone marrow basophils, and explained why they generated fewer cytokines than 
their wild-type counterpart. Their production was enhanced when histamine synthesis was 
blocked by the specific HDC inhibitor 
 
 
 
-fluoro-methyl histidine, and underscored the 
determinant role of histamine in the inhibitory effect. We postulate that pharmacologic 
modulation of histamine transport might become instrumental in the control of basophil 
functions during allergic diseases.
 
Because of their difficult identification and
isolation, the functions of basophils have re-
mained enigmatic for some time. It is well-
established that they play a crucial role during
helminth infections and allergic diseases, and
are most proficient in producing IL-4 to-
gether with histamine, which both facilitate
Th2 differentiation (1–4). Even before com-
plete maturation—when the typical granules
for histamine storage are few—they constitute
an excellent source of pro-Th2 cytokines and
histamine, which they synthesize in response
to growth factors like IL-3 or other stimuli
(5). This newly generated histamine is not
stored inside the cells but is released immedi-
ately to accumulate in the supernatant (5).
We have characterized this low-granule baso-
phil population in murine BM and spleen
using in situ hybridization with the 
 
Hdc
 
 ribo-
probe and ultrastructural criteria (6). Their
number and activity increase strikingly in pe-
ripheral organs during worm rejection (7),
and they are revealed easily by their capacity
to respond to hematopoietic growth factors
(IL-3 or GM-CSF) or aggregated IgE by con-
comitant synthesis of histamine, IL-4, and IL-6
(8, 9). These medullary basophils can take up
histamine from the environment through a
process that does not involve H
 
1
 
, H
 
2
 
, or H
 
3
 
R,
although H
 
3
 
R antagonists compete with his-
tamine for uptake (10, 11). In the present
study we addressed two major issues arising
from these findings: the functions of hista-
mine transported by medullary basophils, and
the identity of the molecule that is responsible
for this process.
 
The online version of this article contains supplemental material.
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Here, we provide the first evidence that histamine can
modulate the biologic activities of basophils through a trans-
port system that is unrelated to its classical receptors, includ-
ing the most recently discovered H
 
4
 
R. We identify the mol-
ecule that mediates this process as organic cation transporter
(OCT) 3, and show that it is inhibited by available H
 
3
 
/H
 
4
 
R
ligands. Furthermore, we demonstrate that this negative
feedback is triggered by an increase of intracellular hista-
mine, which exerts a transcriptional control of its own syn-
thesis and that of associated pro-Th2 cytokines.
 
RESULTS AND DISCUSSION
 
We previously identified a medullary population of basophils
with few granules, which produce histamine—together with
IL-4 and IL-6—in response to IL-3 (6). Knowing that these
cells also can take up histamine from the environment (10),
we examined whether this process affected their typical bio-
logic activities. Hence, we stimulated total or basophil-
enriched BM cells
 
 
 
for 24 h with IL-3 in the presence or ab-
sence of histamine (10
 
 
 
3
 
 and 10
 
 
 
4
 
 M), before measuring
cytokine production in supernatants. As shown in Fig. 1 A,
Figure 1. Histamine and H3/H4R ligands exert a similar inhibition on 
histamine and cytokine production by BM basophils. (A) Effect of 
histamine on IL-3–induced IL-4 and IL-6 production as well as IL-4, 
IL-6, and HDC mRNA expression. Results are means   SEM from three 
separate experiments for BM cells and represent a typical experiment 
for Lin  cells. (B) Effect of H3/H4R ligands on histamine production and 
uptake by BM cells stimulated with IL-3. Data, expressed as percentage 
inhibition relative to controls, are means   SEM from three to seven 
separate experiments. CPF, ciproxifan; MR, carboperamide; CB, cloben-
propit; TP, thioperamide; CZ, clozapine; IM, imetit. (C) Inhibition of 
histamine and cytokine production by BMC in the presence of optimal 
concentrations (10 5 M) of H3/H4R ligands. Data, expressed as percent-
age inhibition relative to controls, are means   SEM from three sepa-
rate experiments.  
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histamine inhibited the generation of IL-4 and IL-6 in total
and mature cell–depleted Lin
 
 
 
 BM cells. This decrease was
preceded by lower mRNA transcription, as measured by
real-time PCR in Lin
 
 
 
 BM cells that were incubated for 4 h
with histamine (10
 
 
 
3
 
 M). Remarkably, transcription of 
 
Hdc
 
,
the gene that encodes the histamine-forming enzyme, also
was diminished (Fig. 1 A).
Based on our previous evidence that H
 
3
 
R antagonists
bind to histamine-producing BM cells and compete with
histamine for uptake (11), we evaluated the effect of these
drugs on histamine and cytokine production measured in
culture supernatants after a 24-h exposure to IL-3. They di-
minished these biologic activities similarly to histamine itself;
the degree of inhibition correlated with their potency as in-
hibitors of histamine uptake (Fig. 1 B). Clobenpropit (CB),
classified as an H
 
3
 
R antagonist and an H
 
4
 
R agonist (12), in-
hibited histamine uptake and synthesis, as did thioperamide,
although it antagonizes H
 
3
 
 and H
 
4
 
 receptor binding. MR
16155 and ciproxifan, two H
 
3
 
R antagonists were the most
potent inhibitors, in contrast with the less effective imetit, an
agonist of H
 
3
 
 and H
 
4
 
R. None of the drugs impaired cell via-
bility, as assessed by trypan blue exclusion or colorimetric
MTT assay (unpublished data).
Depletion of mature cells markedly increased IL-3–
induced histamine production (391.0 
 
 
 
 15.3 ng/10
 
6
 
 Lin
 
 
 
versus 65.7 
 
 
 
 3.9 ng/10
 
6
 
 total BM cells), whereas CB main-
tained a similar inhibition (159.0 
 
 
 
 9.5 ng/10
 
6
 
 Lin
 
 
 
 versus
30.0 
 
 
 
 2.4 ng/10
 
6
 
 total BM cells; means 
 
 
 
 SEM from three
separate experiments). The reduced histamine levels in BM
cell supernatants after exposure to CB were due to lower
histidine decarboxylase (HDC) activity as measured by the
transformation of radiolabeled histidine into histamine
(49,102 
 
 
 
 6,598 dpm/h/mg protein in controls incubated
for 24 h with IL-3 alone versus 25,923 
 
 
 
 5,360 dpm/h/mg
protein in the presence of CB; means 
 
 
 
 SEM from five sep-
arate experiments; P 
 
 
 
 0.05). This was preceded by de-
creased 
 
Hdc
 
 transcription, quantified by real-time PCR after
a 4-h exposure to CB (81.0 
 
 
 
 12.53% decrease relative to
controls; mean 
 
 
 
 SEM from three separate experiments). As
shown in Fig. 1 C, H
 
3
 
/H
 
4
 
R ligands reduced the production
of IL-4 and IL-6 similarly to histamine (Fig. 1 A), and CB
decreased their mRNA expression after a 4-h incubation of
IL-3-induced Lin
 
 
 
 BMC (34.7 
 
 
 
 13.3% for IL-6 and 67.0 
 
 
 
11.4% for IL-4 transcripts; means 
 
 
 
 SEM from three sep-
arate experiments). In further support of the basophilic
identity of histamine-producing cells, IL-3–induced Lin
 
 
 
BM cells produced IL-13, a typical basophil-associated cyto-
kine (1), which was inhibited similarly by CB (212 
 
 
 
 40
and 58 
 
 
 
 3 pg/10
 
6
 
 cells, respectively; means 
 
 
 
 SD from
two separate experiments).
The preferential expression of H
 
4
 
R in the BM (13),
together with its pharmacologic characteristics, suggested
its implication in histamine uptake (14). Yet, although
H
 
4
 
R mRNA was expressed in basophil-enriched BM cells
(Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20050195/DC1), the inhibition exerted by H
 
3
 
/
H
 
4
 
R ligands was not impaired in mice in which the gene
encoding either receptor had been disrupted (Fig. S1; ref-
erences 15 and 16), nor was it diminished in the presence
of the highly specific H
 
4
 
R antagonist JNJ7777120 (not de-
picted; reference 17). Furthermore, blocking H
 
1
 
, H
 
2
 
, and
H
 
4
 
 receptors on BM cells from H
 
3
 
R
 
 
 
/
 
 
 
 mice did not pre-
vent histamine uptake or inhibition of histamine and cy-
tokine synthesis by the drugs (unpublished data); this ruled
out the participation of any classical histamine receptor
alone or in combination.
Recent progress in the characterization of transmem-
brane transporters, which enable small electrically charged
molecules to cross the cell membrane, prompted us to ad-
dress their potential role in histamine uptake by basophils.
Figure 2. OCT3 is expressed and functional in BM-derived baso-
phils. (A) Oct3 and Oct1 mRNAs are detected in basophil-enriched Lin  
BM cells and sorted Fc RI  c-kit  cells, in contrast with Oct2 tran-
scripts. (B) OCT3 substrates inhibit uptake and IL-3–induced synthesis 
of histamine. Data are means   SEM from three separate experiments. 
(C) The prototypical substrate of OCTs, MPP , is taken up by BM baso-
phils and inhibited by D22, CB,  -estradiol, and histamine (data are 
means   SEM from three separate experiments). (D) Electronically 
sorted Fc RI  c-kit  basophils derived from BM cells cultured for 8 d 
in IL-3 take up radiolabeled histamine and MPP  and respond to CB, 
MPP , and D22 by decreasing their IL-3–induced histamine synthesis 
(data represent a typical experiment out of three). 
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One member of the organic cation transporter family (18–
20), OCT3, was particularly interesting in our model be-
cause of its relatively broad tissue distribution and usage of
histamine as substrate (18). 
 
Oct3
 
 mRNA was detected easily
in basophil-enriched Lin
 
 
 
 BM cells and Fc
 
 
 
RI
 
 
 
 
 
c-kit
 
 
 
 ba-
sophils sorted after 8 d of culture in IL-3 (Fig. 2 A). Tran-
scripts for 
 
Oct1, which cannot transport histamine (18), also
were detected, whereas Oct2 mRNA was not (Fig. 2 A).
We examined the effect of several substrates or inhibitors of
OCT3 in our experimental set up, namely decynium 22
(D22),  -estradiol, and corticosterone. As shown in Fig. 2
B, they reduced uptake and synthesis of histamine by BM
cells that were exposed to IL-3, in accordance with their re-
ported potencies for OCT3 (18–20). In contrast, tetraethyl-
ammonium, which recognizes human OCT1 and OCT2,
but not human OCT3, had no such effect (Fig. 2 B). Using
radiolabeled 1-methyl-4-phenylpyridinium (MPP ), the
prototypical substrate of OCTs, we found that it was effec-
tively taken up by BM cells and inhibited by OCT3 sub-
strates, CB, and unlabeled histamine (Fig. 2 C). The low ef-
ficiency of histamine in inhibiting MPP  uptake probably is
explained by its exclusive transport by OCT3 because it
fails to label OCT3 /  BM cells (see Fig. 4 A), whereas
MPP  also can interact with OCT1 (18), as confirmed by
its residual labeling of OCT3 /  BM cells (not depicted).
As shown in Fig. 2 D, [3H]histamine and [3H]MPP  uptake
was enhanced greatly among sorted Fc RI  c-kit  baso-
phils (50 times on average), and inhibited by CB, MPP ,
and D22; this proved that OCT3 is associated effectively
with the basophil lineage. The transporter was clearly func-
tional in these purified basophils because the large amounts
of histamine generated in response to IL-3 were decreased
markedly in the presence of the drugs.
The bidirectional mode of action of OCT3 (19, 20),
which is shared by the histamine transporter we reported
previously (21), provides an explanation for the paradox
that H3/H4R ligands and inhibitors of OCT3 exert the
same effect on basophils as histamine itself. As shown in
Fig. 3 A, a 24-h incubation with CB significantly increased
intracellular histamine levels in BM cells, whereas overall
production and extracellular concentrations diminished.
This intracellular increase was observed in response to all
inhibitory drugs (Fig. 3 B). It is most likely due to a partial
blockade of the outward transport after neosynthesis. Com-
monly, cellular secretion occurs through a regulated or a
constitutive process. It is plausible that the latter mecha-
nism, which takes place continuously in many cells and
does not involve granules, can be controlled by OCT3.
The localization of intracellular histamine is likely to be
important for the efficiency of the negative feedback be-
cause exogenous histamine at inhibitory doses induced 10-
fold greater intracellular levels than those generated endog-
enously in response to IL-3 and trapped inside the cells by
the blockade of OCT3 (117   12% increase after a 24-h
exposure to IL-3   CB, versus 1,623   234% after uptake
of exogenous histamine; means   SEM from five different
experiments). It is possible that histamine distributes differ-
ently inside the cells, depending on its origin. In its newly
synthesized form it may remain in the cytosol preferen-
tially, ready to exert its negative feedback, whereas exoge-
nous histamine could be taken up and stored immediately
in vesicles or granules, and thus, prevent most of its inhibi-
tory action. This immediate storage of exogenous hista-
mine was demonstrated for mast cells (22). Although the
intracellular localization of histamine is important, it re-
mains possible that OCT3 ligands enter the cells and syner-
gize with histamine to enhance the susceptibility of baso-
phils to the negative feedback. Whatever the mechanism,
the inhibition of cytokine production by CB depends on
newly synthesized histamine, because it was diminished
strikingly in Hdc-deficient mice (23), whereas exogenous
Figure 3. Clobenpropit requires intracellular histamine for its 
inhibitory effect. (A) CB increases the intracellular histamine content 
of BM cells stimulated for 24 h with IL-3, whereas extracellular and total 
histamine decrease (means   SEM from three separate experiments). 
(B) All inhibitory drugs tested increased the proportion of intracellular 
histamine in BM cells, relative to its overall IL-3–induced production 
(means   SEM from three separate experiments). (C) The inhibition of 
IL-6 production by CB (10 5 M) is diminished strikingly in BM cells from 
histamine-deficient HDC /  mice, whereas exogenous histamine (HA, 
10 3 M) remains effective. Data are means   SEM from three separate 
experiments. (D) Histamine deficiency does not affect histamine uptake, 
and its inhibition by ciproxifan (CPF) and CB (data are means   SEM 
from three separate experiments).JEM VOL. 202, August 1, 2005 391
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histamine conserved its effect (Fig. 3 C). It also was de-
creased when histamine synthesis was blocked by  -fluoro-
methyl histidine ( -FMH), the suicide substrate of HDC
(unpublished data). The disruption of the Hdc gene had no
effect on histamine uptake and its inhibition by CB and
ciproxyfan, as shown in Fig. 3 D.
Ultimate proof of the implication of OCT3 in histamine
uptake and the ensuing diminution of the biologic activities
of basophils was provided by the use of BM cells from mice
in which the corresponding gene had been disrupted (24).
These cells neither took up [3H]histamine (Fig. 4 A), nor
was their cytokine production affected by histamine, CB, or
D22 (Fig. 4 B). In accordance with the notion that OCT3
behaves like a release valve for newly synthesized histamine,
its intracellular levels were higher in BM cells from Oct3-
deficient mice than in their wild-type counterparts, both
spontaneously and in response to a 24-h exposure to IL-3
(Fig. 4 C). In contrast, extracellular histamine levels were
significantly lower in BM cells from mice that lacked
OCT3 than in controls (Fig. 4 D), as was total histamine
production. Exocytosis of the few granules present in BM
basophils (6) or vesicular secretion (piecemeal degranula-
tion), reported for basophils cultured in IL-3 (25), could ac-
count for the residual release in Oct3-deficient mice (Fig. 4
D). IL-6 and IL-4, generated during a 24-h incubation with
IL-3, were decreased in BM cell supernatants from OCT3-
deficient mice, relative to wild-type controls (Fig. 4 E).
This result indicates that in the absence of the transporter,
when release of newly synthesized histamine is hampered,
its intracellular levels increase sufficiently to trigger the neg-
ative feedback signal. In support of this notion, we found
that IL-3–induced IL-4 and IL-6 synthesis in Oct3 /  BM
cells was enhanced significantly when histamine synthesis
was abrogated by  -FMH, the specific inhibitor of HDC
(74   21% and 51   12% increase in IL-3–induced IL-4
and IL-6 production, respectively; means   SEM from
three separate experiments).
The mechanism by which intracellular histamine de-
creases the transcription of cytokine and HDC genes re-
mains unknown. Involvement of molecules of the cyto-
chrome P450 (CYP450) family is most likely because it was
shown that they bind histamine (26). Furthermore, their
heme moiety recognizes various histamine receptor antago-
nists, particularly H3 receptor antagonists, such as thiopera-
mide, CB, and ciproxifan (27), which were effective in our
experimental set up.
In conclusion, we postulate that OCT3 participates in
the control of histamine and pro-Th2 cytokine synthesis by
modulating intracellular histamine levels. Once it has at-
tained a critical concentration in the cytosol, histamine is
ready to exert its negative feedback control; this alleviates its
deleterious effect during allergic reactions, and hampers the
development of Th2 immune response (28).
MATERIALS AND METHODS
Mice and reagents. 6–8-wk-old C57BL/6 mice, bred in our own facil-
ity, were used. Hdc /  mice were generated by Ohtsu et al. (23). H4R- and
H3R-deficient mice were provided by Johnson & Johnson Pharmaceutical
Research Department and Development, L.L.C., whereas Oct3 /  mice
Figure 4. OCT3 and the transport system of histamine are identical. 
(A) Oct3 deficiency abolishes histamine uptake, as compared with wild-type 
FVB/N BM cells (data are means   SEM from five separate experiments). 
(B) Oct3 deficiency prevents the inhibitory effect of histamine, CB, and 
D22 on IL-3–induced IL-6 production by BM cells (data are means   SEM 
from four separate experiments). (C) Intracellular histamine is increased in 
BM cells from Oct3 /  mice, whether they were stimulated for 24 h with 
IL-3 or not. (D) In contrast, histamine levels in supernatants as well as 
total histamine production are decreased. (E) IL-3–induced IL-6 and IL-4 
production by BM cells from Oct3 /  mice is significantly lower than in 
wild-type controls. (Data are means   SEM from four separate experiments; 
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were produced by Zwart et al. (24). Recombinant murine IL-3 and DuoSet
ELISA IL-4 and IL-6 kits were purchased from R&D Systems. MR16155
(carboperamide) and ciproxifan were from Bioproject, and CB dihydrobro-
mide was from Tocris. The specific H4R antagonist, JNJ7777120, was de-
veloped and provided by Johnson & Johnson (17). [3H]methyl-4-phenyl-
pyridinium was purchased from Biotrend Chemikalien. All other histamine
receptor ligands and OCT3 substrates, as well as the irreversible HDC in-
hibitor,  -FMH, were from Sigma-Aldrich.
Cell cultures and flow cytometry.  BM cells were prepared as reported
(5) and adjusted to a final concentration of 2.5   106 per ml in culture me-
dium (MEM) supplemented with 10% horse serum (all from GIBCO BRL).
Various doses (10 5–10 9 M) of the drugs were added shortly before the ad-
dition of IL-3 (1 ng/ml), followed by a 24-h incubation at 37 C, 5% CO2.
In some experiments, BM cells were enriched for histamine-producing cells
using the SpinSep depletion kit (StemCell Technologies Inc.), which elimi-
nates cells bearing lineage-specific antigens (Lin ), according to the manu-
facturer’s instructions. Basophil-enriched populations also were derived from
total BM cells according to Yoshimoto et al. (29). After 8–9 d of culture
with IL-3, the proportion of basophils was identified by their Fc R  c-kit 
phenotype. In some experiments, these cells were sorted using a FACSVan-
tage (Becton Dickinson). They were 98% pure upon reanalysis, and con-
tained a majority of cells with basophil morphology as assessed by MGG.
Cytokine assays, measurement of histamine production, and up-
take.  IL-6 and IL-4 production was measured in cell supernatants recov-
ered after a 24-h incubation. Histamine was quantified by an automated
continuous flow spectrofluorometric technique (5). For binding experi-
ments, 106 total BM cells, 105 Lin , and 50,000 Fc RI  c-kit  cells were
plated in round-bottomed 96-well polypropylene plates (Costar). Unless
stated otherwise, the cells were incubated (37 C, 5% CO2) for 3 h with 3
 Ci/ml of [3H]histamine dihydrochloride (2.5   10 7 M; 12 Ci/mmol) or
2  Ci/ml of MPP  (2.5   10 8 M; 80 Ci/mol) in a final volume of 100  l.
Competition assays were performed as previously described (10,11). Each
experiment was performed in triplicate, and histamine binding was calcu-
lated from total cpm after subtraction of nonspecific binding to filters. HDC
assays in cell lysates were performed as previously described (5).
mRNA expression. RNAs were extracted from 2   106 cells by TRIzol
(Invitrogen), according to the supplier’s recommendations. Primers and
probes for mouse IL-4, IL-6, HDC, and GAPDH real-time PCR were de-
signed using the Computer Primer Express software (Applied Biosystems),
except for H4R primers that were provided by F. Cogé (Servier Laboratory,
Servier, France). All other oligonucleotides were purchased as HPLC-purified
molecules from Eurogentech. PCR reactions contained 1  l cDNA samples
at different dilutions, 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 5 mM MgCl2,
200  M deoxyribonucleoside triphosphate, 100 nM of each primer, 200 nM
of the specific probe, 60 nM passive reference (Rox), and 0.5 U hot gold star
Taq DNA polymerase (Eurogentech). Each amplification was performed in
triplicate using the following conditions: 2 min at 50 C and 10 min at 94 C,
followed by 45 cycles of 15 s at 94 C and 30 s at 60 C. All data were normal-
ized to an internal standard—the GAPDH expression in each sample—and
expressed as relative expression using the   CT method as described in the
User Bulletin #2 from Applied Biosystems.
The probes carried a 5  FAM reporter label and a 3  dark quencher
group and were synthesized by Eurogentech.
Statistics. The standard Student’s t test was used to establish statistical
significance.
Online supplemental material. Fig. S1 shows histamine uptake and neg-
ative feedback on histamine and cytokine production by basophils is not me-
diated through H3/H4R. The primers and probes for qualitative and quanti-
tative PCR analyses are described online. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20050195/DC1.
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